| Metric | Value (₹ Cr) |
|---|---|
| Revenue | 42.55 |
| Total Income | 42.57 |
| Expenditure | 35.79 |
| PBT | 6.77 |
| Net Profit | 5.07 |
| OPM | — |
| NPM | 11.91% |
| EPS | 9.89 |
97% growth, 45% guidance: The H2 test Nanta must pass
Nanta delivered a blowout H1 with 97.7% revenue growth and 131% PAT growth. Yet the company guided for 45–50% full-year growth, flagging sharp H2 deceleration. The market has marked it down 51% from its all-time high despite the execution—a miss that matters.
₹42.5 Cr
+97.7% YoY
₹5.1 Cr
+131.4% YoY
23.3%
+900 bps YoY
45–50%
revenue growth
Nanta delivered textbook execution in H1 FY27. Revenue of ₹42.5 Cr grew 97.7% year-on-year, driven by 200 robot deployments and the company's shift toward higher-margin robotics and AI work. Net profit surged 131% to ₹5.1 Cr, with EBITDA margins expanding a stunning 900 basis points to 23.3%. All claims made on the call—growth, margins, unit deployments—have been corroborated by the filed result. By any measure, this is strong.
The story, though, sits in the gap. FY27 full-year guidance of 45–50% growth is a dramatic deceleration from the 97.7% run-rate already posted in H1 alone. This implies H2 must slow to single digits or low teens—a cliff, not a glide. Management frames this as realistic caution; the market is reading it as a warning. And there's a second red flag: the company has guided for EBITDA margins of 20–22% for the full year, which is materially below the 23.3% already delivered in H1, signaling expected mix pressure or cost inflation as the year progresses.
What management claimed vs. what holds up
H1 revenue INR 42.6 Cr with 97.7% YoY growth
Delivered Q2 FY27: ₹42.5 Cr (matches exactly)
Supported
PAT INR 5.1 Cr, up 131.4% YoY; PAT margin 11.9%
Delivered: ₹5.1 Cr PAT, 11.9% margin. Math checks: 5.1÷42.5 = 12%. Growth: 5.1 vs 2.2 prior = +131.8%
Supported
EBITDA INR 9.9 Cr, margin 23.3%, up 900 bps YoY
9.9÷42.5 = 23.3%. Prior H1 FY26: ₹3.1 Cr (7.3% margin). 900 bps confirmed
Supported
45–50% full-year FY27 growth is achievable and reflects market reality
H1 achieved 97.7%. FY27 guidance of 45–50% implies <0% to +20% H2 growth. Sustainable? Unproven
Overstated—guidance implies severe H2 slowdown, not validated
EBITDA margin 20–22% for full year FY27
H1 already delivered 23.3%. Guidance implies margin contraction YoY
Contradicted—guidance sits below H1 run-rate, signaling mix dilution or cost pressure
What changed on this call
RaaS model gaining momentum: now ~50% of H1 unit deployments; expected to increase in H2
Manufacturing model shifted to asset-light: signed MOU with Amitron (INR 10 Cr over 15 months); in-house assembly line by year-end
Segment focus narrowed: hospitality, warehouse automation, and defense are now explicit pillars; pulling back from consumer verticals
Order book visibility new: INR 60 Cr at end H1; anchors include Complex Cinema (₹4.4 Cr, 36 months), Pointer Insurance (₹6 Cr indicative), Amitron deal, and defense Phase-1
No FY28 target set: MD declined to confirm prior INR 200 Cr (March 2026 call) or any FY28 revenue goal; said 'focused on FY27 first'
How the street is positioned
Price action and valuation context. Nanta trades at ₹315 as of 2026-11-05, down 51.6% from its all-time high of ₹651.4. The stock sits above its 20-day SMA (₹312.89) but trades well below both the 50-day (₹333.14) and 200-day (₹366.33) moving averages, signaling a downtrend. RSI of 48.4 is neutral, neither oversold nor overbought. The 52-week range of ₹234–₹651.4 shows the stock has recovered 34.6% from its lows, but remains in the lower third of its yearly band. The drawdown from ATH is severe, and the price action does not reflect the strong H1 execution just reported.
Institutional flows. FII ownership has collapsed: from 2.15% in Q3 FY26 → 0.89% in Q4 FY26 → 0.00% in Q1 FY27 (a 215 basis point exodus in two quarters). DII has also trimmed, from 10.47% → 4.27% → 0.72% (down 975 basis points in the same span). Promoter ownership remains stable at 57.36%. The institutional pullback accelerated even as fundamentals improved—a tell that the market is pricing in execution risk or valuation concerns that the H1 print has not yet resolved.
What the tape is saying. The market's markup from ₹234 (low) to ₹651 (ATH) was a bet on early-stage robotics execution. The subsequent 51% drawdown reflects either (a) fear that H2 slowdown is real and guidance itself is at risk, (b) concern that RaaS model and asset-light manufacturing create unpredictable timing and margin pressure, or (c) simple valuation reset—a micro-cap roboticist in a nascent market may not command premium multiples even at 97% growth. The all-institutional outflows and the price stuck below its 50-day and 200-day averages suggest the market is still in wait-and-see mode despite strong results.
The bull-bear ledger
Execution on H1 targets was flawless: 97.7% growth, 131% PAT growth, 200 robot deployments all corroborated
Margin expansion is structural, not one-time: driven by higher-margin robotics mix (30–35% capex EBITDA vs 12–20% RaaS)
Order book visibility (₹60 Cr) provides 1–2 quarters of revenue runway
Large TAM in hospitality, warehouse, manufacturing, and defense; global robotics market USD 107 Bn by 2030
FY27 guidance (45–50%) is *much* lower than H1's 97.7% run-rate; implies sharp H2 slowdown or guidance miss risk
Margin guidance (20–22%) sits below H1's 23.3%, signaling expected mix or cost pressure in H2
No in-house manufacturing yet; dependent on Amitron outsourcing through EOY 2026
RaaS model complexity: 24–48 month payoff cycles, ties up capex, creates revenue timing risk
Customer concentration: top 2–3 deals (Complex Cinema, Pointer Insurance, Amitron, defense) represent material % of ₹60 Cr order book
FII/DII have exited 215/975 basis points respectively in 2 quarters; market still pricing execution risk
Risks, ranked by how much they should concern a holder
1
HighH2 slowdown materializes; FY27 guidance missed
H1 achieved 97.7% growth, but FY27 guidance of 45–50% implies <20% H2 growth. If H2 comes in below guidance, the stock will re-rate sharply lower. Visibility into H2 order execution is the critical near-term test.
2
HighMargin dilution if RaaS model scales too aggressively
RaaS margins (12–20% AMC) are half of capex margins (30–35%). FY27 guidance for 20–22% EBITDA (vs 23.3% H1) signals this is already expected. If RaaS mix accelerates beyond plan, margins could compress further.
3
MediumManufacturing capacity bottleneck or Amitron delay
In-house assembly line not live until EOY. Any delay in Amitron's delivery or supply chain hiccup directly throttles H2/FY28 output. Company lacks control over this critical input.
4
MediumCustomer concentration; top 2–3 deals are major revenue sources
Complex Cinema and Pointer Insurance deals are large relative to ₹60 Cr order book. Early termination, scope cut, or integration failure at these customers would materially impact revenue and cash flow timing.
5
MediumNo FY28 target; guidance trajectory unclear
MD explicitly declined to confirm prior INR 200 Cr FY28 target or set new guidance. Market will be in limbo post-FY27 on whether Nanta is a 30% grower or a 100%+ grower. This uncertainty depresses valuation.
6
LowTechnology and IP obsolescence in fast-moving robotics sector
Nanta has 17 in-house robot models and proprietary software, but global players (ABB, KUKA, Boston Dynamics) have vastly larger R&D budgets. India-specific TAM focus helps, but tech risk remains for early-stage roboticist.
What to watch next
1 · Q3 FY27 order inflow and deployment ramp
The test is simple: do the 800+ robot deployments targeted for H2 materialize? Complex Cinema, Pointer Insurance, and defense Phase-1 are the big bets. If Q3 shows order delays, customer POC extensions, or deployment slippage, the H2 slowdown is real and FY27 guidance is at risk.
2 · Margin trajectory in Q3; RaaS mix % disclosed
FY27 guidance of 20–22% EBITDA is below H1's 23.3%. If Q3 margins continue to compress below 23%, it suggests RaaS is scaling faster than expected or costs are rising. If margins stabilize above 22%, mix is controlled.
3 · FY28 guidance pre-announcement or call confirmation
MD avoided FY28 targets on H1 call. By Q3/Q4, the market will demand clarity. If Nanta confirms 40–50% CAGR multi-year, moat strengthens. If FY28 guidance is vague or conservative, the market will assume management sees demand headwinds.
The single number to track
FY27 full-year revenue. If Nanta delivers on its 45–50% full-year growth guidance, the company will post ₹58–61 Cr revenue for FY27 (assuming FY26 base of ~₹40–43 Cr). This will validate management's H2 slowdown thesis and keep guidance credibility intact. If actual FY27 revenue undershoots 45% (i.e., comes in below ₹58 Cr), the stock will re-rate lower; if it overshoots 50% (i.e., ₹61 Cr+), the FY27 guidance was overly conservative and multi-year acceleration is credible. This one number will determine whether Nanta is a disciplined, de-risking growth story or a momentum miss waiting to happen.
Nanta Tech delivered impressive H1 execution. Revenue, profit, and unit deployments all came in as promised, and margins expanded sharply. The company is not a story of accounting creativity or one-time items—the growth is organic and the operational leverage is real. But the market is right to be cautious. The 97.7% H1 growth-to-45–50% full-year guidance reset is a red flag, not a baseline. Margin guidance sitting below H1 run-rate signals expected dilution. No FY28 target and a sharp institutional exit (FII gone, DII halved) tell you the market is pricing execution and visibility risk. Nanta must now prove H2 delivers on the 800+ robot deployment target and that margins hold. If it does, the 51% drawdown from ATH will look cheap in hindsight. If it doesn't, the stock has further to fall. This is a Hold—strong execution, but unproven sustainability and too much H2 risk to buy into the strength. Wait for Q3 to show H2 is real.
Strong execution delivers 97% growth; H2 deceleration priced in
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 7/10
Grade B
H1 result hit exactly; FY27 guidance is conservative but unproven. No prior stated guidance to track.
Optimistic
next 1–2 quarters
Optimistic
multi-year
Nanta delivered 97.7% H1 revenue growth with PAT surging 131.4%, validating execution. However, full-year guidance of 45–50% growth signals sharp H2 deceleration; margins are strong (23.3% EBITDA) but company remains early-stage with in-house manufacturing not yet live, creating execution risk. Order visibility (INR 60 Cr) is decent but insufficient to de-risk a small-cap roboticist in a nascent market.
₹42.5 Cr
Revenue · +97.7% YoY₹5.1 Cr
Reported PAT · +131.4% YoYExpanding
Margins · vs guidance: CorroboratedDid the claims hold up?
H1 FY27 revenue INR 42.6 Cr with 97.7% YoY growth
METDelivered Q2 FY27: ₹42.5 Cr (matches exactly; note: this is H1 data, not Q2 alone)
PAT INR 5.1 Cr, up 131.4% YoY; PAT margin 11.9%
METDelivered: ₹5.1 Cr PAT, 11.9% margin (5.1÷42.5=12%). Growth math: 5.1 vs 2.2 prior = +131.8%
EBITDA INR 9.9 Cr, margin 23.3%, up 900 bps YoY
METEBITDA 9.9÷42.5 = 23.3% margin. Prior H1 FY26: INR 3.1 Cr (7.3% margin). 900 bps expansion confirmed
Order book INR 60 Cr at end of H1; 200 robots deployed, targeting 800+ in H2
UnverifiedNot in delivered financials; unverifiable from FY27 result
45–50% full-year FY27 revenue growth is achievable and sustainable multi-year
OVERSTATEDH1 achieved 97.7%. Guidance of 45–50% implies sharp H2 deceleration. Sustainability claim unproven
Earnings quality
What changed since the last call
Order book visibility
NewINR 60 Cr at end H1 (from INR 86.6 Cr mid-H1? unclear). RaaS model gaining traction; 50/50 capex/service mix now.
Guidance reset downward on annualized basis
Downgrade45–50% FY27 guidance vs 97.7% H1 run-rate implies sharp H2 slowdown; consistency concern for full-year visibility.
Manufacturing moat & asset-light model
NewSigned MOU with Amitron for outsourced manufacturing; assembly line by EOY. Shifts from COGS to software/IP revenue streams.
Segment focus clarified
NewManagement explicitly targeting hospitality (hotels, hospitals, corporates) and warehouse automation for next 5 years; pulling back on consumer/other verticals.
The Q&A
Analyst questions were mostly constructive and execution-focused. No hostile pushback observed. Achuth asked tough questions on manufacturing capex and prior guidance targets (INR 200 Cr FY28), which MD deflected by saying FY28 target is not finalized. Tone remained cordial; MD held firm on 45–50% FY27 growth despite H1's 97.7%.
FY27 Growth Guidance — Garvit Goyal, Serene Alpha
AnsweredMD: 45–50% growth for full year. We are very confident and margins will be better because robotics/AI is our higher-margin business.
Margin Drivers — Garvit Goyal, Serene Alpha
AnsweredMD: Robotics/AI business mix is growing significantly. That vertical has higher margins than AV business, so product mix is driving margin expansion.
Long-term CAGR Sustainability — Garvit Goyal, Serene Alpha
PartialMD: Yes, we are very confident that will be sustained and may even grow much higher in the future.
Robot Deployments & Use Cases — Aviral Sharma, Finvenue Investments
AnsweredMD: ~200 deployed in H1. Majority are cleaning robots. Targeting 800+ in H2. Currently 50/50 split between outright sales and service model.
RaaS Model Transition — Aviral Sharma, Finvenue Investments
AnsweredMD: Currently ~50/50. In H2, seeing shift toward RaaS (Robot-as-a-Service) model; clients prefer recurring revenue over upfront capex.
FY28 Revenue Target — Achuth, Duchan Bank
DodgedMD: (did not confirm prior INR 200 Cr target; only said) 45–50% growth expected this year. We are not setting FY28 target yet; focused on completing FY27 aggressively.
IP Ownership & Licensing Model — Garvit Goyal, Serene Alpha
AnsweredMD: 17 robot models in-house. Hardware components sourced from partners; 80% software/firmware is proprietary (MeetIQ, NTalk, Ntra, VisitQ, etc.). AMC contracts: 12–20% of hardware value annually.
Defense Segment Order Value — Kundan K, Sapphire Capital
PartialMD: It's a Phase-1 pilot project. Value is not large compared to our business (implied <INR 5 Cr), but it's strategic for government sector positioning and future phases.
Manufacturing Capacity & Amitron Deal — Achuth, Duchan Bank
AnsweredMD: No in-house capacity yet. Signed MOU with Amitron for outsourced manufacturing (~INR 10 Cr orders over 15 months). Assembly line ready by end of FY27.
RaaS Margin Profile — Maitri, Sapphire Capital
AnsweredMD: Capex direct deployment: ~30–35% EBITDA margin. RaaS: lower upfront, 12–20% AMC margin. Payoff period 24–48 months depending on deal size.
Capex vs RaaS Mix Going Forward — Maitri, Sapphire Capital
PartialMD: RaaS will grow at much larger scale. Clients prefer it. We are working on managing high capex upfront; solutions expected to roll out soon.
Competition & Entry Barriers — Garvit Goyal, Serene Alpha
AnsweredMD: Very few competitors in India. Entry barrier is high: requires mechanical + design + AI + software integration expertise. Most companies lack this depth.
FY28 Revenue Targets — Maitri, Sapphire Capital
DodgedMD: We have not set FY28 targets. Focused on completing FY27 targets aggressively first. Will assess and set next year.
Guidance
FY27 full-year: 45–50% revenue growth
HighBase FY26 ~INR 40–45 Cr (est.). H1 FY27 already at INR 42.5 Cr (+97.7%). H2 must decelerate sharply to hit 45–50% full-year.
FY27 EBITDA margin: 20–22% range (vs 23.3% in H1)
MediumAssumes RaaS mix shift and manufacturing ramp-up. H1 achieved 23.3%; full-year guidance is *below* H1 run-rate, implying either product mix dilution or one-time charges.
Risks the call surfaced
Execution (H2 slowdown)
HighH1 achieved 97.7% growth; FY27 guidance of 45–50% full-year is *much* lower. This implies H2 growth of <0–20%, creating sharp deceleration. If H2 underperforms, FY27 guidance will be missed.
Manufacturing & Capex
MediumNo in-house manufacturing capacity yet. Amitron deal signed for outsourcing (INR 10 Cr over 15 months). Assembly line ready by EOY 2026. Delays or supply chain hiccups could throttle H2/FY28 growth.
Customer Concentration
MediumComplex Cinema INR 4.4 Cr over 36 months; Pointer Insurance INR 6 Cr indicative. These 2 deals alone ~INR 10 Cr. Order book is INR 60 Cr, so these represent ~17% of visible pipeline. Larger deals likely concentrated.
Market & Demand Risk
MediumRobotics/AI solution sales depend on customer willingness to deploy capex. Long POC cycles (1.5–2 years), complex integration, high hardware+software complexity. Macro slowdown or customer budget cuts could delay orders.
RaaS Model Profitability
MediumRaaS is recurring revenue but ties up capex. Early stages of this model; scale-up required. If customer defaults or early termination, capex loss.
Technology & Product Risk
LowNanta is building in-house (via TRN, Robotics Nexus platform). However, global players (ABB, KUKA, Boston Dynamics, etc.) have vastly larger R&D budgets. Tech obsolescence risk in a fast-moving sector.
Defense Segment Execution
MediumDefense order is 'not very big' in Phase 1 but strategic for future. Implementation timelines unpredictable in government/defense. Multi-phase contracts have execution risk.
Management
Score 7/10. MD is talkative and provides detailed operational explanations (e.g., 17 robot models, IP ownership, RaaS mechanics, competition analysis). Transparent on challenges (no in-house manufacturing, RaaS complexity). However, some repetition and circular explanations. Avoids FY28 target question; frames as 'not decided yet.' H1 results fully validate FY27 growth trajectory (97.7% YoY vs 45–50% guidance suggests ultra-conservative guidance or real H2 slowdown risk). No prior guidance track record to evaluate, but current FY27 numbers on track.
1 · Q3 FY27
Defense Phase-1 prototype delivery expected Dec 2026; initial order value undisclosed
2 · Q4 FY27
In-house robot assembly line ready; Complex Cinema 100-AT deployment ramp (INR4.4 Cr over 36 months)
3 · FY28
RaaS model scale-up; Amitron manufacturing orders (INR 10 Cr+ indicative value over 15 months)
Order visibility (INR 60 Cr) is decent but insufficient to de-risk a small-cap roboticist in a nascent market.